Anzeige
Mehr »
Samstag, 01.04.2023 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H80W ISIN: CH0100191136 Ticker-Symbol: V6MS 
Berlin
28.06.19
20:00 Uhr
0,000 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RELIEF THERAPEUTICS HOLDING AG Chart 1 Jahr
5-Tage-Chart
RELIEF THERAPEUTICS HOLDING AG 5-Tage-Chart

Aktuelle News zur RELIEF THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
RELIEF THERAPEUTICS Aktie jetzt für 0€ handeln
22.03.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023823Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration...
► Artikel lesen
17.03.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting1.496Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited...
► Artikel lesen
16.03.Relief Therapeutics Holding SA: Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe340Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe 16.03.2023 / 07:00 CET/CEST Relief Therapeutics...
► Artikel lesen
15.03.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA900Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA 15-March-2023 / 07:00 CET/CEST Release of an ad hoc announcement...
► Artikel lesen
28.02.Relief Therapeutics Holding SA: Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars810Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars 28.02.2023 / 07:00...
► Artikel lesen
14.02.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa1.015Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis...
► Artikel lesen
08.02.Relief Therapeutics Holding SA - 6-K, Report of foreign issuer23
08.02.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Provides an Update on its Financing Strategy782Relief Therapeutics Holding SA / Key word(s): Financing Relief Therapeutics Provides an Update on its Financing Strategy 08-Feb-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant...
► Artikel lesen
07.02.Swiss rare disease biopharma Relief Therapeutics withdraws $25 million US IPO13
17.01.Relief Therapeutics gets review board nod for trial of blood cancer therapy20
17.01.Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom867 Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell...
► Artikel lesen
27.12.22Acer Therapeutics Inc.: Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders29
27.12.22Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission2.139Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission 27-Dec-2022...
► Artikel lesen
27.12.22Adhoc: Relief Therapeutics Holding SA: Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders1.642Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders 27-Dec-2022...
► Artikel lesen
23.12.22Swiss drug developer Relief Therapeutics upsizes proposed offering to $25M17
23.12.22Swiss rare disease biopharma Relief Therapeutics sets terms for $25 million US IPO17
23.12.22Relief Therapeutics Holding SA - F-1/A, Registration statement for certain foreign private issuers9
20.12.22Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements1.269Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements 20-Dec-2022 / 07:00 CET/CEST Release...
► Artikel lesen
14.12.22Relief Therapeutics Holding SA: Relief Therapeutics to Participate in January Investor Meetings409Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in January Investor Meetings 14.12.2022 / 07:00 CET/CEST Relief Therapeutics to Participate...
► Artikel lesen
13.12.22Relief Therapeutics announces issuance of 1B shares from authorized capital7
Seite:  Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4